Cyclacel Pharmaceuticals, based in Berkeley Heights, New Jersey, develops cancer medicines focusing on cell cycle and transcriptional regulation. Its key programs include fadraciclib and plogosertib, targeting solid tumors and hematological malignancies.
David E Lazar sold 194,628,820 shares of CYCC on 26 February at $0.03 per share, worth a total of $5.5M. They now own 0 CYCC shares, or a 100% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
